Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBecoming pregnant while taking Wegovy (semaglutide) is biologically possible, and a small number of people do conceive during treatment. Wegovy is not a contraceptive. However, semaglutide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, because its safety for a developing baby has not been established. If you are planning a pregnancy, or think you may already be pregnant, speak to your prescriber or GP before taking your next dose. This page covers what the evidence says, what remains uncertain, and how to plan safely, drawing on NHS guidance on semaglutide and current MHRA-approved prescribing information.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
No. Wegovy does not act as contraception, and conceiving while on it is entirely possible. This is a question our prescribers hear most weeks, and the answer surprises many people, partly because weight loss itself can restore or improve fertility. Conditions such as polycystic ovary syndrome (PCOS) are closely linked to body weight, and as weight falls, ovulation can become more regular and predictable than it was before. That is genuinely good news for long-term reproductive health, but it does mean the window during which an unplanned pregnancy could occur is real and worth planning around. The Wegovy treatment page sets out how semaglutide works for weight management more broadly.
If you are sexually active and not planning a pregnancy, reliable contraception throughout treatment is important. For most people, a combined oral contraceptive or progestogen-only pill remains appropriate. Unlike tirzepatide, there is currently no evidence that semaglutide reduces the absorption of oral contraceptive pills, so the usual pill rules apply. That said, your prescriber is the right person to confirm which method suits your individual circumstances if you are wondering whether you can get pregnant on Wegovy.
Animal studies conducted during Wegovy's clinical development raised concerns about adverse effects on fetal development at exposures above the therapeutic human dose. Human data are limited, clinical trials excluded pregnant participants, so we do not have large controlled safety studies in people. This absence of evidence is not the same as evidence of safety, and regulators including the MHRA have therefore classified semaglutide as not recommended during pregnancy rather than proven safe. You can read the prescribing details in the Wegovy Summary of Product Characteristics on the eMC.
If pregnancy is confirmed while you are on Wegovy, the medicine should be stopped. There is no established evidence that a single dose taken unknowingly before pregnancy was detected causes harm, but continuing treatment is not appropriate. For a fuller picture of what being pregnant on Wegovy means for your care and next steps, contact your GP or obstetric team promptly so that your pregnancy can be monitored as normal and any concerns can be assessed early. Our support team can help you reach your prescriber quickly if you have an urgent clinical question outside of a GP appointment.
Current guidance, reflected on the NHS England weight-management injections page, recommends stopping semaglutide at least two months before attempting to conceive. This wash-out period allows the medicine to clear your system before early fetal development begins. Semaglutide has a half-life of roughly one week, so it takes several weeks for plasma levels to fall significantly after the last dose.
Two months is a minimum guide, not a guarantee, and your own situation matters. If you have been on a higher maintenance dose or have other health conditions relevant to pregnancy, your GP or specialist may advise a longer gap. It is also worth discussing what happens to your weight management during that period: stopping treatment without a plan can lead to weight regain, which has its own implications for conception and pregnancy health. The page on falling pregnant on Wegovy goes into more depth on how to structure that transition.
Try not to panic. Taking a dose or two before a positive pregnancy test is not an established cause of harm, and many people in this position go on to have uncomplicated pregnancies. What matters now is acting promptly: stop taking Wegovy, make an appointment with your GP to let them know, and ensure your antenatal care starts as planned. You can also report the exposure through the MHRA's Yellow Card scheme, which helps build the safety evidence base for medicines used inadvertently in pregnancy. The scheme is straightforward and your midwife or GP can help you complete it.
Further questions about Wegovy use in pregnancy are answered in detail on the Wegovy and pregnancy page, including what antenatal monitoring is usually recommended. If you want to understand what alternatives exist for weight management once a pregnancy is confirmed, speaking to a clinician is the right first step, some lifestyle support programmes remain appropriate throughout pregnancy, even when medicines are paused. You can also find out more about whether Wegovy is used for type 2 diabetes on our dedicated page, and explore what a clinical assessment with our prescribers covers on the weight-loss treatments page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.